Validation of the 70-Gene Signature in Tumor Stage
(A) Patients were separated according to early- and advanced-stage cancer. (B–E) The 70-gene signature was applied to cancer patients of all stages (B), early stage (C), advanced stage (D), and advanced stage after 9 months (E). Each group was classified by the 70-gene signature into low and high risk, and evaluated by Kaplan-Meier analysis. The p values were computed by the log rank test.